Navigation Links
Significant Generic Erosion Will Cause Sales of Dyslipidemia Drugs to Decline by $3.6 Billion by 2016
Date:3/19/2008

Statins Will Continue to Dominate Market Despite Patent Expiries and Increased Use of Fixed-Dose Combinations, According to a New Report from

Decision Resources

WALTHAM, Mass., March 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that sales of dyslipidemia therapies will decline from $28 billion in 2006 to $24.4 billion in 2016 owing to significant generic erosion, triggered particularly by the 2006 U.S. patent expiry of Merck's Zocor and the U.S. and European patent expiries of Pfizer's Lipitor beginning in 2010.

The new Pharmacor report entitled Dyslipidemia finds that statins will continue to dominate the dyslipidemia drug market by claiming more than 70 percent patient share in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. However, the sales share of statins will decline from $21 billion in 2006 to $7.8 billion in 2016 owing to generic erosion and greater use of fixed-dose combination therapies that offer dual modes of action and/or modulate high-density lipoprotein (HDL) in addition to low- density lipoprotein (LDL) cholesterol. The fixed-dose combinations class will capture 30 percent of the dyslipidemia market in 2016.

The report also finds that physicians will increasingly prescribe treatment aimed at aggressive LDL targets in high-risk patients, which will benefit more potent agents such as AstraZeneca's Crestor and add-on therapies such as Merck/Schering-Plough's Zetia/Ezetrol. Aggressive treatment will also boost uptake of novel LDL-lowering therapies such as lapaquistat, Takeda's novel squalene synthase inhibitor, which will be used in polypharmacy regimens.

"Although statins are entrenched as the first-line therapy of choice for the vast majority of dyslipidemia patients and have achieved success in lowering both LDL and the risk of heart attacks, the prevalence of both coronary heart disease and mortality remain unacceptably high," said Donny Wong, Ph.D., principal analyst at Decision Resources. "As a result, the medical community is increasingly targeting non-LDL lipid abnormalities, and despite the recent discontinuation of Pfizer's torcetrapib in Phase III development, physicians believe that well-tolerated therapies that target low or dysfunctional HDL can still play a vital role in primary and secondary prevention."

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be

trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Carnegie Mellon study shows just listening to cell phones significantly impairs drivers
2. NeurogesX to Present at Susquehanna Financial Groups 2nd Annual SIGnificant Options in Healthcare Conference
3. Novavax CEO to Present at Susquehannas Second SIGnificant Options in Healthcare Conference
4. Abaxis, Inc. to Present at the Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
5. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
6. Advanced Life Sciences to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference
7. Significant Growth for Pinstripe Leads to Need for Larger Facility
8. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
9. AAAS symposium to address significant effects of the male parent in reproductive success
10. Peter G. Peterson Commits $1 Billion Toward Solving Americas Most Significant Economic Challenges
11. Surprising New Research Indicates that Significant Numbers of Children as Young as 11 are Engaging in Sexual Activity and that Dating Violence and Abuse are Part of Their Relationships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... ... personal financial planning to families and business owners in North Central West Virginia, ... help provide services to differently abled residents in the region. , The Stepping ...
(Date:6/22/2017)... , ... June 22, 2017 , ... Plastic Surgery Associates ... a Top Doctor for 2017. Each year, research and information firm, Castle Connolly, releases ... the title in 2015, this marks the 3rd time that Dr. Canales ...
(Date:6/22/2017)... Washington, DC (PRWEB) , ... June 22, 2017 ... ... awarded a $3.7 million grant from the American Heart Association (AHA) to launch ... economic incentives to improve the prevention and diagnosis of rheumatic heart disease (RHD) ...
(Date:6/22/2017)... ... 22, 2017 , ... Vighter, a premier provider of Unconventional ... ANSI/ASIS PSC.1-2012. The company’s work in countries throughout Southwest Asia, South America, and ... been degraded. The PSC.1 standard was created to protect fundamental freedoms and human ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, a ... Nashville-based private equity firm, has invested $3.35 million in the company. , ... Claritas Capital offers the smart money, speed to market and accountability we had ...
Breaking Medicine News(10 mins):
(Date:6/10/2017)... Ala. , June 9, 2017  Shane K. Burchfield, DPM, ... recognized for excellence as a Podiatrist in Alabama ... Podiatry at Family First Foot Care. He brings over 20 years ... medicine, pain management and healthcare, to his role. ... First Foot Care, PC is pleased to welcome you ...
(Date:6/8/2017)... June 8, 2017  Less than a month ago, ... than 200,000 companies, including hospital networks, in over 150 ... one of the largest online extortion attempts ever recorded. ... market, it is imperative that providers understand where the ... from this — and many other very real cyber ...
(Date:6/7/2017)... June 7, 2017 Endo International plc (NASDAQ: ... 2017, the Hon. Joseph R. Goodwin , U.S. ... West Virginia , entered a case management ... Repair System Products Liability Litigation (the "MDL") that includes ... to provide expert disclosures on specific causation within one ...
Breaking Medicine Technology: